Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma

Investor logo

Warning

This publication doesn't include Faculty of Education. It includes Faculty of Science. Official publication website can be found on muni.cz.
Authors

ŠTEFANČÍKOVÁ Lenka MOULIS Mojmír FABIAN Pavel VÁŠOVÁ Ingrid ZEDEK František RAVČUKOVÁ Barbora MUŽÍK Jan KUGLÍK Petr VRANOVÁ Vladimíra FALKOVÁ Iva HRABÁLKOVÁ Renata ŠMARDOVÁ Jana

Year of publication 2011
Type Article in Periodical
Magazine / Source International Journal of Oncology
MU Faculty or unit

Faculty of Science

Citation
Doi http://dx.doi.org/10.3892/ijo.2011.1170
Field Genetics and molecular biology
Keywords diffuse large B-cell lymphoma; tumor suppressor p53; FASAY; overall survival; progression free survival
Description We performed complex analysis of the p53 tumor suppressor in collection of 75 DLBCL cases. Fifty four patients were de novo cases, twenty one cases developed into DLBCL by transformation from less aggressive disease. We determined functional status by analysis of separated alleles in yeast (FASAY) and analyzed the p53 mutations by cDNA sequencing. We assessed the level of the p53 protein by immunoblotting analysis. We used FISH to analyze loss of the p53 and ATM (ataxia telangiectasia mutated) genes deletion. We detected 16 p53 mutations (21.3%) including the mutation activating nonsense-mediated RNA decay pathway. Deletion of the p53 allele was more common in cases with p53 mutation. Mutations and/or deletions of p53 had statistically significant negative impact on progression-free survival and tended to decrease also overall survival in 46 de novo DLBCL patients treated with R-CHOP. p53 aberrations are negative predictors for survival of DLBCL patients treated with R-CHOP.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.